In a previous study, we identified CPO following a non-target-based high-throughput screening to identify compounds to eliminate LCSCs (AFP+/CD133+cells) and HCCs (AFP+/CD133− cells) without inducing toxicity in hepatocytes (AFP−/CD133+ cells) in mixed populations of HCC cells with hepatocytes. Here, CPO is linked to hepatocellular carcinoma.